Maze Therapeutics, Inc.
Price Action
Technical Summary
CONSOLIDATINGMaze Therapeutics, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is weak (RS Rating: 34), showing significant lag compared to the market leaders. Earnings growth of 40% provides fundamental context to the price action. Investors should exercise caution due to high volatility (87% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $25.27 | +14.78% | ABOVE |
| 50 SMA | $25.77 | +12.52% | ABOVE |
| 100 SMA | $33.53 | -13.50% | BELOW |
| 150 SMA | $36.00 | -19.44% | BELOW |
| 200 SMA | $34.15 | -15.09% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is MAZE in an uptrend right now?
MAZE has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is MAZE overbought or oversold?
MAZE's RSI (14) is 67. The stock is in neutral territory, neither overbought nor oversold.
Is MAZE outperforming the market?
MAZE has a Relative Strength (RS) Rating of 34 out of 99. MAZE is currently lagging the broader market.
Where is MAZE in its 52-week range?
MAZE is trading at $29.00, which is 54% of its 52-week high ($53.65) and 42% above its 52-week low ($10.98).
How volatile is MAZE?
MAZE has a Beta of 1.00 and 52-week volatility of 87%. It's less volatile than the S&P 500 - generally more stable.